rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AGEN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial - Slideshow

      2026-11-14. The following slide deck was published by Agenus Inc.

      Nov 14Seeking AlphaAGEN
      Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
      Nov 6Yahoo FinanceAGEN
      Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

      LEXINGTON, Mass., November 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were pres

      Nov 6Yahoo FinanceAGEN
      Agenus (AGEN) Q3 Earnings Meet Estimates
      Nov 6Yahoo FinanceAGEN
      Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
      Nov 5Yahoo FinanceAGEN
      Agenus earnings beat by $0.08, revenue topped estimates
      Nov 5Investing.comAGEN
      Agenus advances Phase 3 colon cancer trial, posts Q3 profit
      Nov 5Investing.comAGEN
      Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

      LEXINGTON, Mass., November 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026.

      Nov 2Yahoo FinanceAGEN
      Agenus reports positive results from UNICORN colon cancer trial
      Nov 2Investing.comAGEN
      Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
      Nov 2Yahoo FinanceAGEN
      Agenus reports response rate in colon cancer trial (AGEN:NASDAQ)
      Oct 25Seeking AlphaAGEN
      Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
      Oct 25Yahoo FinanceAGEN
      Agenus to Provide Third Quarter 2026 Financial Report and Development Update
      Oct 22Yahoo FinanceAGEN
      Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
      Oct 20Yahoo FinanceAGEN
      Agenus at Chardan’s 10th annual healthcare conference: pivot to ROBIN
      Oct 20Investing.comAGEN
      Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
      Oct 9Yahoo FinanceAGEN
      Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
      Oct 8Yahoo FinanceAGEN
      Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
      Oct 8Yahoo FinanceAGEN
      Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

      LEXINGTON, Mass., October 03, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by

      Oct 3Yahoo FinanceAGEN
      Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

      LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

      Oct 2Yahoo FinanceAGEN
      Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - Caution Advised

      Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN stock here.

      Sep 29Seeking AlphaAGEN
      Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN)
      Sep 29Seeking AlphaAGEN
      Agenus Shares Rise After Chardan Initiates Coverage at Buy

      Agenus (AGEN) shares were up nearly 13% in Monday afternoon trading after Chardan initiated coverage

      Sep 28Yahoo FinanceAGEN
      Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday - Kodiak Sciences

      U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.

      Sep 28BenzingaAGENKODMBXAMC
      Rodman & Renshaw initiates Agenus stock with buy on cancer therapy
      Sep 28Investing.comAGEN
      Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
      Sep 20Yahoo FinanceAGEN
      Agenus Inc. (AGEN) Shareholder/Analyst Call - Slideshow (NASDAQ:AGEN) 2026-09-11
      Sep 11Seeking AlphaAGEN
      Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

      LEXINGTON, Mass., September 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

      Sep 10Yahoo FinanceAGEN
      Agenus to Participate in Upcoming September Investor Conferences

      LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.

      Aug 31Yahoo FinanceAGEN
      Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

      LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

      Aug 28Yahoo FinanceAGEN
      Agenus reports survival data for colorectal cancer treatment
      Aug 28Investing.comAGEN
      Agenus reports no cancer recurrences in colon cancer trial
      Aug 26Investing.comAGEN
      Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

      LEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled "Neoadjuvant botensilimab/balstilimab for localized mismatch re

      Aug 26Yahoo FinanceAGEN

      This is the newest page. Registered accounts read further back.